Our innovative R&D solutions (InnoRD™) reduce the time of your development
as we develop the best preclinical models for your needs.
Complex animal models of cardiovascular and metabolic diseases (diabetes, hyperlipidemia, atherosclerosis, obesity, aging) for proof-of-concept studies:
- myocardial infarction and ischemia/reperfusion (we use our
newly developed software for infarct size evaluation infarctsize™ 1.0)
- cardioprotection and heart failure
- hyperlipidemia, hypercholesterolemia, atherosclerosis (diet, genetic)
- diabetes (type 1 and type 2 diabetes models in mice and
rats, diet, genetic models)
- nitrate tolerance
- systemic inflammatory response syndrome (e.g. septic shock)
- in vivo cardiac gene and cell transfer for target
validation
| Evaluation of compounds acting on the nitric oxide-cGMP system and peroxynitrite formation, e.g. peroxynitrite scavengers | |
 |
Measurements: NO (electron
spin resonance spectroscopy), NO synthase (NOS) activities, cGMP
production, superoxide formation, peroxynitrite formation, in vitro
peroxynitrite scavenger assays, MDA, etc.
|
| Effects of cardioprotective compounds on myocardial ischemia, preconditioning, doxorubicin-induced heart failure, and vascular functions in hyperlipidemia/atherosclerosis and nitrate-tolerance models. | |
|
Measurements: plasma lipids,
cardiac function, infarct size,
vascular flow, myocardial enzyme release, histomorphologic changes,
electrohpysiology, arrhythmias, and any biochemical parameters in
diet-induced rat and rabbit models and transgenic mice models of
experimental hypercholesterolemia, atherosclerosis, and
nitrate-tolerance.
|
| Evaluation of antidiabetic componds in type 1 and type 2 diabetic models (STZ, Goto-Kakizaki, Zucker Diabetic Fatty, etc). | |
|
Measurements: glucose,
insulin, pancreatic insulin, peptide C, HgbA1c, etc.
|
| Evaluation of cardiac heat-shock protein (HSP) inducers. | |
|
Measurements: cardiac hsp
mRNA and HSP protein contents in ischemia/reperfusion or heat stress,
Hsp transgenic models.
|
| Evaluation of matrix metalloproteinase (MMP) inhibitors. | |
|
Measurements: MMP activities
and protein contens in vivo and ex vivo. In vitro MMP inhibition
assays.
|
| Evaluation of cardioprotective and/or antiarrhythmic compounds in myocardial ischemia/reperfusion or preconditioning in isolated heart, in vivo rodent models. | |
|
Measurements: cardiac
function, infarct size, arrhythmias, enyzme release, high energy
phosphates, histomorphology, electrophysiology, biochemical analysis of
heart tissue and perfusate for any targets of your choice.
|
| Assessment of the antioxidant efficacy of cardiovascular drugs by means of direct detection of oxygen free radicals and nitric oxide with electron spin resonance spectroscopy in ischemia/reperfusion. | |
|
Measurements: oxygen free radical production, pro- and antioxidant enzyme activities |
| Chronic heart failure model of in vivo coronary artery occlusion plus isolated rat heart for evaluation of chronic administration of cardioprotective drugs. | |
|
Measurements: cardiac
function, infarct size, and histomorphologic changes in working hearts
isolated from rats subjected to in vivo permanent ligation of the main
coronary artery.
|